Immune competence in a patient with Hodgkin's disease and relapsing toxoplasmosis
- PMID: 77257
- DOI: 10.1007/BF01642165
Immune competence in a patient with Hodgkin's disease and relapsing toxoplasmosis
Abstract
A 40 year old woman with Hodgkin's disease twice developed signs of encephalitis while being treated with prednisone and cyclophosphamide for 10 months. Since on both occasions her Toxoplasma dye test titer was 1 : 8000 or higher, she was treated on suspicion of toxoplasmosis with sulfadizine and pyrimethamine. Her tumor therapy was changed to bleomycin with lower doses of prednisone for 12 months. After death from central pontine myelinolysis, Toxoplasma and cytomegalovirus could be isolated, but no lesions attributable to these infectious agents were present. Maintenance of the patient's immune competence suggested an inquiry into the effects of the chemotherapeutic agents and of tumor infiltration for their respective interference with immunity. Using hamsters with chronic latent toxoplasmosis, it was found that both cortisone and cyclophosphamide caused recrudescence of chronic inapparent infection, that vinblastine and bleomycin interfered only slightly with the development of immunity, whereas in infiltrating lymphoma permitted immunity to develop normally. It is concluded that greater attention should be directed to the immunosuppressive effects of tumor treatment. By choice of an effective tumor therapy which is least immunosuppressive, and if necessary under cover of antimicrobial therapy, a patient with Hodgkin's disease can be aided in developing immunities which he may subsequently be able to maintain.
Similar articles
-
Immunosuppression and toxoplasmic encephalitis: clinical and experimental aspects.Hum Pathol. 1975 Jan;6(1):97-111. doi: 10.1016/s0046-8177(75)80111-0. Hum Pathol. 1975. PMID: 1110086
-
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.J Clin Oncol. 2005 Oct 20;23(30):7555-64. doi: 10.1200/JCO.2005.08.138. J Clin Oncol. 2005. PMID: 16234521
-
Favorable outcome of central nervous system toxoplasmosis occurring in a patient with untreated Hodgkin's disease.Cancer. 1980 Feb 15;45(4):808-10. doi: 10.1002/1097-0142(19800215)45:4<808::aid-cncr2820450433>3.0.co;2-c. Cancer. 1980. PMID: 7357497
-
An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.Yonsei Med J. 2005 Jun 30;46(3):425-30. doi: 10.3349/ymj.2005.46.3.425. Yonsei Med J. 2005. PMID: 15988816 Free PMC article. Review.
-
[Comparative study of advanced-stage Hodgkin's lymphoma patients treated with either COPP or ABVD drug combinations].Orv Hetil. 1992 Jun 21;133(25):1561-3. Orv Hetil. 1992. PMID: 1383902 Review. Hungarian.
Cited by
-
Toxoplasmosis an Overlooked Disease: Seroprevalence in Cancer Patients.Asian Pac J Cancer Prev. 2018 Jul 27;19(7):1987-1991. doi: 10.22034/APJCP.2018.19.7.1987. Asian Pac J Cancer Prev. 2018. PMID: 30051689 Free PMC article.
-
The antinflammatory effects of glucocorticosteroids. A brief review of the literature.Inflammation. 1979 Jul;3(3):329-43. doi: 10.1007/BF00914190. Inflammation. 1979. PMID: 383608 Review.
-
Diagnosis of toxoplasmosis using DNA probes.J Clin Pathol. 1990 Mar;43(3):260-1. doi: 10.1136/jcp.43.3.260-b. J Clin Pathol. 1990. PMID: 2135733 Free PMC article. No abstract available.
-
Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis.Front Microbiol. 2017 Mar 9;8:389. doi: 10.3389/fmicb.2017.00389. eCollection 2017. Front Microbiol. 2017. PMID: 28337191 Free PMC article.
-
Tamoxifen Increased Parasite Burden and Induced a Series of Histopathological and Immunohistochemical Changes During Chronic Toxoplasmosis in Experimentally Infected Mice.Front Microbiol. 2022 May 30;13:902855. doi: 10.3389/fmicb.2022.902855. eCollection 2022. Front Microbiol. 2022. PMID: 35707167 Free PMC article.